Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt
Authors:
- Eytan AbrahamEAEytan Abraham
- Nuala TrainorNTNuala Trainor
- Nicholas OstroutNONicholas Ostrout
- Matthew M. HewittMHMatthew M. Hewitt
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 20
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK CellsFrontiers in Immunology, 2020
- The necessity of automated manufacture for cell-based immunotherapies: a cost-based analysisCell & Gene Therapy Insights, 2020
- Cancer cell therapies: the clinical trial landscapeNature Reviews Drug Discovery, 2020
- Accelerating the development of innovative cellular therapy products for the treatment of cancerCytotherapy, 2020
- The Emerging Landscape of Immune Cell TherapiesCell, 2020
- Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cellsScientific Reports, 2019
- Decentralized manufacture of cell therapies: the challenge of operational modelingCell & Gene Therapy Insights, 2019
- Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell TherapyCurrent Hematologic Malignancy Reports, 2018
- How short-term gain can lead to long-term painCell & Gene Therapy Insights, 2017
- Difference between hematological malignancy and Solid tumor research articles published in four major medical journalsLeukemia, 2006